1-2 of 2
Jonathan Weiss
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax

Available to Purchase
Moritz Fürstenau, Jonathan Weiss, Adam Giza, Fabian Franzen, Sandra Robrecht, Anna-Maria Fink, Kirsten Fischer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Barbara Eichhorst, Michael Hallek, Paula Cramer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4203–4211.
https://doi.org/10.1158/1078-0432.CCR-22-0433
Published: 03 October 2022
View articletitled, Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Open the PDF for Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax in another window
Includes: Supplementary data
Journal Articles

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Free
Johannes M. Heuckmann, Michael Hölzel, Martin L. Sos, Stefanie Heynck, Hyatt Balke-Want, Mirjam Koker, Martin Peifer, Jonathan Weiss, Christine M. Lovly, Christian Grütter, Daniel Rauh, William Pao, Roman K. Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7394–7401.
https://doi.org/10.1158/1078-0432.CCR-11-1648
Published: 30 November 2011
View articletitled, ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Open the PDF for ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors in another window
Includes: Supplementary data